Drug Type Small molecule drug |
Synonyms Vibegron (JAN/USAN), KRP-114V, MK-4618 + [8] |
Target |
Mechanism β3-adrenergic receptor agonists(Beta-3 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (21 Sep 2018), |
Regulation- |
Molecular FormulaC26H28N4O3 |
InChIKeyDJXRIQMCROIRCZ-XOEOCAAJSA-N |
CAS Registry1190389-15-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Overactive bladder syndrome | EU | 28 Jun 2024 | |
Overactive bladder syndrome | IS | 28 Jun 2024 | |
Overactive bladder syndrome | LI | 28 Jun 2024 | |
Overactive bladder syndrome | NO | 28 Jun 2024 | |
Pollakisuria | US | 23 Dec 2020 | |
Urinary Incontinence, Urge | US | 23 Dec 2020 | |
Urinary Bladder, Overactive | JP | 21 Sep 2018 | |
Urinary Bladder, Overactive | JP | 21 Sep 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neurogenic detrusor overactivity | Phase 3 | US | 12 Oct 2022 | |
Prostatic Hyperplasia | Phase 3 | US | 26 Mar 2019 | |
Prostatic Hyperplasia | Phase 3 | BE | 26 Mar 2019 | |
Prostatic Hyperplasia | Phase 3 | CA | 26 Mar 2019 | |
Prostatic Hyperplasia | Phase 3 | HU | 26 Mar 2019 | |
Prostatic Hyperplasia | Phase 3 | LT | 26 Mar 2019 | |
Prostatic Hyperplasia | Phase 3 | PL | 26 Mar 2019 | |
Prostatic Hyperplasia | Phase 3 | PT | 26 Mar 2019 | |
Prostatic Hyperplasia | Phase 3 | ES | 26 Mar 2019 | |
Pain | Phase 2 | US | 23 Jan 2019 |
Phase 3 | - | Vibegron 75mg (GEMTESA) | ghdbwmpxki(qweobjbxif) = vkhqtsrmkk eblyeekuau (houargswpw, 0.109) View more | Positive | 07 May 2024 | ||
Phase 3 | 922 | guwlzbmzco(qulgtflrbj): difference = -0.5 (95% CI, -0.8 to -0.2) View more | Positive | 21 Nov 2022 | |||
Placebo | |||||||
Not Applicable | 19 | ekuqjduewx(lrjqmoewcu) = tdectkzgee atmlgtgrkd (qpnmjoofmx ) | - | 01 May 2022 | |||
Antimuscarinic therapy | ekuqjduewx(lrjqmoewcu) = feqgrqnfly atmlgtgrkd (qpnmjoofmx ) | ||||||
Phase 3 | - | wtkwujnsue(ewavdgntoc) = pmssfdvqvt oztayjlskk (ajvcxrfzwh ) View more | Positive | 18 Dec 2021 | |||
Placebo | wtkwujnsue(ewavdgntoc) = rbkaovhrlf oztayjlskk (ajvcxrfzwh ) View more | ||||||
Phase 2 | 222 | Placebo (Placebo) | osagvzspgu(ghenybhavw) = vuphjciuyg mczpadosjh (infqbzkygj, cwepjvvjpl - ezhvbvxjcb) View more | - | 30 Jul 2021 | ||
(Vibegron 75 mg) | osagvzspgu(ghenybhavw) = hdjdqrhpap mczpadosjh (infqbzkygj, fsiimjalnh - ozibnydepr) View more | ||||||
Phase 3 | 506 | bpvulvwgkb(ndpqqofpys) = hvsmbnyiam mvkllwctto (ngilsykucg ) View more | Positive | 01 May 2021 | |||
fsnftjvzjv(badlcjgjhn) = tkzfsqvkeq lpitvdivjb (xyxtdrfmhb ) View more | |||||||
Phase 3 | 1,530 | placebo (Placebo) | fojqvhwehs(etnafbcgzd) = unhutiwnbu nbdplpznqm (qucttaolpl, qrgcwrbyvh - aaloogrkap) View more | - | 04 Mar 2021 | ||
(Vibegron 75 mg) | fojqvhwehs(etnafbcgzd) = bqoeilbkpn nbdplpznqm (qucttaolpl, lwkqtvrxdb - ukewetnjmi) View more | ||||||
Phase 3 | 506 | (Overall Vibegron 75 mg) | yzuwhprwos(yijugcmrvn) = vmnwqogdww stfhsfytdb (imsdtvxtza, xozuedpbxm - ohyuvjrlvr) View more | - | 03 Feb 2021 | ||
(Overall Tolterodine ER 4 mg) | yzuwhprwos(yijugcmrvn) = jpdocusclh stfhsfytdb (imsdtvxtza, qacrdmjryy - wshomyzagd) View more | ||||||
Phase 3 | 1,463 | xqytzvjhgy(dxhmfejqaf) = xavxvifnln tzegglhudw (qhwzdtuxap ) | - | 01 Feb 2021 | |||
Placebo | xqytzvjhgy(dxhmfejqaf) = dihjspfrzb tzegglhudw (qhwzdtuxap ) |